Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study

CONCLUSIONS: ICI rechallenge therapy beyond disease progression did not improve clinical outcomes in patients with NSCLC, but no new safety signals emerged. However, patients with favorable response to initial ICIs treatment still showed significant efficacy of subsequent ICI rechallenge therapy.PMID:38617775 | PMC:PMC11009570 | DOI:10.21037/jtd-23-1767

Source: Journal of Thoracic Disease - April 15, 2024 Category: Respiratory Medicine Authors: Xiaoqi Yan Luqing Zhao Fei Wu Bo Shen Guoren Zhou Jifeng Feng Chao Yue Jingni Zhu Shaorong Yu Source Type: research